Neuburgh Advisers’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Neuburgh Advisers’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$169K	Hold	2,992	–	–	0.01%	712
2019 Q2	$166K	Hold	2,992	–	–	0.01%	725
2019 Q1	$151K	Hold	2,992	–	–	0.01%	728
2018 Q4	$121K	Buy	2,992 +578	+24%	+$29.8K	﹤0.01%	740
2018 Q3	$167K	Buy	2,414 +204	+9%	+$15.5K	0.01%	729
2018 Q2	$167K	Hold	2,210	–	–	0.01%	694
2018 Q1	$117K	Buy	2,210 +374	+20%	+$21.7K	﹤0.01%	763
2017 Q4	$98K	Buy	1,836 +340	+23%	+$18.9K	﹤0.01%	793
2017 Q3	$89K	Buy	1,496 +442	+42%	+$26.7K	﹤0.01%	781
2017 Q2	$83K	Buy	1,054 +578	+121%	+$47.3K	﹤0.01%	768
2017 Q1	$39K	Buy	+476	New	+$35.4K	﹤0.01%	804

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Neuburgh Advisers's EGRX Position: Q3 2019 in Review

Neuburgh Advisers held its Eagle Pharmaceuticals, Inc. (EGRX) position steady in Q3 2019 at 2,992 shares worth $169K. The position accounts for 0.01% of the portfolio, ranked #712.

Neuburgh Advisers first reported a position in EGRX in Q1 2017 and has held it in 11 quarters since. 183 funds tracked by Wall St. Rank hold EGRX as of Q3 2019.

Neuburgh Advisers held 2,992 shares of Eagle Pharmaceuticals, Inc. worth $169K as of Q3 2019.
Neuburgh Advisers left its Eagle Pharmaceuticals, Inc. share count unchanged in Q3 2019.
Eagle Pharmaceuticals, Inc. made up 0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #712 holding.
Neuburgh Advisers first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2017 and has held it in 11 quarters since.
183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.